SUMMARY Synovial fluid samples (139) from 121 patients with rheumatoid arthritis, osteoarthritis, pseudogout, chronic pyrophosphate arthritis, gout, and reactive arthritis were analysed for cartilage proteoglycan components. Keratan sulphate (KS) epitope was determined by a competitive radioimmunoassay, and total sulphated glycosaminoglycans (S-GAG) were determined after papain digestion by a specific dye binding assay. Increased concentration of both KS epitope and S-GAG were found in synovial fluid from joints with acute inflammatory arthropathy (gout, pseudogout, and reactive arthritis). Analysis of consecutive samples from the same joint at different stages showed that the concentration of KS epitope or total S-GAG varied with acute inflammatory activity. In samples from patients with chronic conditions during active and inactive inflammatory phases concentrations were much lower and not distinguishable among these disease groups. The detection of raised concentration of proteoglycan components may reflect the rapid depletion or greatly increased turnover of proteoglycan in the articular cartilage during acute inflammation in the joint. This did not appear to be sustained in most patients with chronic joint diseases. 
glycans are complex macromolecules (Mr 1-4x 106) and consist of an extended protein core, to which are attached many glycosaminoglycan chains (chondroitin sulphate and keratan sulphate). 9 10 In normal cartilage proteoglycans are slowly but continuously turned over, the degraded molecules are released from the cartilage and are replaced by newly synthesised components.5 11 It is the coordinate control of synthesis and degradation of the matrix components by the chondrocytes that maintains normal cartilage. In experimental models of joint disease, however, there is evidence of changes in the rates of biosynthesis and turnover of proteo- glycans, which may contribute to cartilage degeneration. '2 17 The degradation products of proteoglycan turnover are released from the cartilage matrix and appear in the synovial fluid and serum. It is therefore possible that concentrations of proteoglycan components in body fluids, particularly in synovial fluid, may reflect metabolic changes occur-may enable cartilage degeneration to be detected and monitored and thereby help more effective treatments to be developed.
In this study we determined the concentrations of proteoglycan in synovial fluids from patients with well characterised joint diseases (rheumatoid arthritis, osteoarthritis, acute and chronic pyrophosphate arthropathy, gout, and reactive arthritis). In addition, the results were correlated with the clinical assessment of joint inflammation (inactive or active) at the time of aspiration to determine whether there is a correlation between increased proteoglycan release from cartilage and clinically assessed disease activity. 
GLYCOSAMINOGLYCANS (S-GAG)
Before assay the synovial fluid samples were digested by incubation with papain overnight at 60°C. The reaction was stopped by heating the samples at 100°C for 15 minutes. The concentration of S-GAG in the synovial fluids was determined with 1,9-dimethylmethylene blue in a newly developed automated procedure.24 Briefly, 40 p1 of shark chondroitin sulphate standard (5-40 tg/ml) or sample diluted in 0.05 M sodium acetate pH 6-8 was added to wells of a 96 well microtitre plate, and to each well was added 250 tl of the dye in a formate buffer pH 3.5. 24 The absorbance (at wavelength 600 nm) of the wells was determined immediately. The change in absorbance (a negative change at 600 nm) was calculated from the mean absorbance of four blank wells in which only sample buffer and dye were added. The concentration of S-GAG in the samples was determined from the linear portion of the chondroitin sulphate standard curve (5-40 Zg/ ml). The microtitre plate reader was interfaced with a Norsk minicomputer to facilitate calculation of the results. With this system both chondroitin sulphate and keratan sulphate can be detected without interference from hyaluronate (high molecular weight or oligosaccharide). The concentration of KS epitope in the synovial fluids of patients with acute gout, acute pseudogout, and reactive arthritis (all clinically assessed as active) was significantly raised (p<0.001) (Fig. 1) .
In the synovial fluids of patients with acute pseudogout 10 out of 14 contained KS epitope at concentrations above 50 PG units/ml, the mean value was 156 PG units/ml, and the maximum concentration detected was 480 PG units/ml. The synovial fluid of one patient with acute gout also had a high concentration of KS epitope. In the synovial fluids of patients with reactive arthritis three out of four patients had concentrations above 50 PG units/ml (mean value 107*7 PG units/ml, maximum concentration 192 PG units/ml). The synovial fluids of four patients with RA showing active inflammation also contained KS epitope at concentrations above 50 PG units/ml (range 97-147).
Total glycosaminoglycans The concentration of proteoglycans was also determined in the same synovial fluids (Fig. 2) using a dye binding assay that detects all the S-GAG (chondroitin sulphate and keratan sulphate) which form a major part of the proteoglycan structure. 27 In synovial fluids from patients with clinically inactive and 49 gig/ml respectively. In the synovial fluids of patients with active RA most also had concentrations of S-GAG below 100 Fg/ml (mean 62 jig/ml), but six samples had concentrations above this (106-218 ,ug/ml) and these included the four samples that had significantly raised concentrations of KS epitope.
The concentrations of total S-GAG in the synovial fluids of patients with pseudogout (mean 118 Ztg/ml), acute gout (mean 314 I,g/ml), and reactive arthritis (mean 99 ,ug/ml) were significantly higher than those of the other patient groups (p<0-01). There was no significant difference between the acute crystal arthropathy and reactive arthritis (p>0.5).
A comparison of the concentrations in the synovial fluids of KS epitope and total S-GAG showed considerable variation between individuals in their content of the keratan sulphate structure responsible for the epitope. Those synovial fluids containing raised concentrations of KS epitope also had raised levels of S-GAG. Overall, the KS epitope determinations appeared to show more discrimination between the high concentrations found in acute inflammatory conditions and the lower values of other samples. Five patients with CPA and superimposed pseudogout attacks underwent serial sampling of the same knee during different phases of clinical activity. Determinations of KS epitope and total S-GAG were made on these samples (Fig. 3) . When joints were assessed as showing active clinical inflammation many showed raised concentrations of KS epitope. Of these, the highest values were seen during acute pseudogout attacks where all samples had raised concentrations. 16 17 There is therefore a need to study the very early stages of disease, but it may be difficult to identify 'patients' at preclinical stages and would require the identification of at-risk groups. In established clinical groups the value of determination would be improved if the total volume of synovial fluid and the rate of proteoglycan clearance were measured so that a rate of release of proteoglycan could be calculated. This is impractical for all patients, and although Saxne et al reported that volume determinations did not significantly alter the basic trend of results,n a limited study would enable the importance of these parameters to be assessed. Evidence from the sequential sampling of patients suggests that each individual shows little variation in proteoglycan concentration when sampled at different times compared with the large variation evident in all the clinically defined groups. The development of longitudinal studies may thus reveal more from patients with chronic disease than is evident merely from comparison of data from the different disease groups. Some results have shown that for patients with RA whose synovial fluids were sampled 10 years ago the concentration of synovial fluid proteoglycan showed a direct correlation with the subsequent extent of cartilage damage (joint space narrowing).31 Longitudinal studies of patients from the earliest stages of disease will help to substantiate these results and establish if there are phases of proteoglycan release that are of predictive value in different chronic joint diseases. 
